Pharvaris (NASDAQ:PHVS) Reaches New 1-Year High – Here’s What Happened

Posted by Francis Steltz on May 14th, 2026

Pharvaris N.V. (NASDAQ:PHVS – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $33.33 and last traded at $32.94, with a volume of 231127 shares changing hands. The stock had previously closed at $31.25.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Wolfe Research assumed coverage on Pharvaris in a report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price target on the stock. Wall Street Zen downgraded Pharvaris from a “sell” rating to a “strong sell” rating in a report on Monday, April 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Citigroup reiterated a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Finally, Wedbush lifted their price target on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Pharvaris has a consensus rating of “Moderate Buy” and an average price target of $49.18.

Get Our Latest Report on Pharvaris

Pharvaris Stock Performance

The company has a 50 day moving average of $27.99 and a two-hundred day moving average of $26.48. The stock has a market capitalization of $2.15 billion, a PE ratio of -10.36 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS – Get Free Report) last announced its earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.15). As a group, research analysts predict that Pharvaris N.V. will post -3.14 EPS for the current fiscal year.

Insider Activity at Pharvaris

In other Pharvaris news, insider Anne Lesage sold 21,700 shares of the firm’s stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $30.26, for a total value of $656,642.00. Following the completion of the transaction, the insider owned 56,450 shares of the company’s stock, valued at approximately $1,708,177. This trade represents a 27.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Johannes Gerardus Chri Schikan sold 29,070 shares of the firm’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $30.32, for a total transaction of $881,402.40. Following the completion of the transaction, the director directly owned 355,167 shares of the company’s stock, valued at approximately $10,768,663.44. This represents a 7.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 150,659 shares of company stock worth $4,489,587. Corporate insiders own 11.84% of the company’s stock.

Institutional Trading of Pharvaris

Several large investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System grew its stake in Pharvaris by 2.2% during the 4th quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock valued at $666,000 after purchasing an additional 520 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in Pharvaris during the 4th quarter valued at about $35,000. Public Employees Retirement System of Ohio grew its stake in Pharvaris by 20.7% during the 4th quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock valued at $210,000 after purchasing an additional 1,300 shares during the last quarter. Finally, Legal & General Group Plc grew its stake in Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares during the last quarter.

About Pharvaris

(Get Free Report)

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.